| Research background and objectiveOvarian cancer is a common malignant tumor in women with high degree of malignancy,strong invasiveness,no specific manifestations of early lesions,and the lack of effective treatment for advanced diseases,resulting in poor quality of life and prognosis of ovarian cancer patients.Currently,the main treatment for ovarian cancer is tumor cell reduction combined with chemotherapy containing platinum-containing drugs,and some patients are expected to benefit from targeted therapy.However,ovarian cancer has a serious problem of drug resistance to chemotherapy,which has become a key problem of chemotherapy failure and high mortality,and there is no effective prognostic marker for ovarian cancer.TRIM 14,as an important member of the TRIM family of proteins,plays an important regulatory role in the occurrence and development of various malignant tumors.However,the role and mechanism of TRIM 14 in the occurrence and development of ovarian cancer have not been confirmed.This study aims to evaluate the potential role and clinical significance of TRIM 14 in prognostic prediction of epithelial ovarian cancer by detecting the expression of TRIM 14 in epithelial ovarian cancer tissues and analyzing its relationship with related clinicopathological parameters and prognosis.Materials and methods1、GEPIA2 and HPA databases were used to analyze the differential expression of TRIM 14 mRNA and TRIM 14 protein in epithelial ovarian cancer and normal ovarian tissue.The Kaplan-Meier Plotter database was used to analyze the association between TRIM 14 expression and progression-free survival and overall survival in epithelial ovarian cancer patients.2、A total of 102 cases of epithelial ovarian cancer diagnosed in our hospital from 2015 to 2017 were collected,among which 48 cases were taken platinum free interval(PFI)as reference.Epithelial ovarian cancer was divided into sensitive group(PFI≥6 months)and resistant group(PFI<6 months)in response to platinum-based chemotherapy drugs.The expression of TRIM 14 protein in epithelial ovarian cancer tissues was detected by immunohistochemical staining,and the expression of TRIM14 mRNA in sensitive and drug-resistant groups was detected by real-time quantitative PCR.3、SPSS Statistics26.0 was used for data integration analysis,and Chi-square test was used to analyze the correlation between the expression of TRIM14 and clinicopathologic features of epithelial ovarian cancer patients.The correlation between TRIM 14 expression and overall survival(OS)and progression free survival(PFS)of epithelial ovarian cancer patients was analyzed by Kapaln-Meier univariate analysis.Multivariate COX regression analysis was performed to determine the independent risk factors affecting the prognosis of epithelial ovarian cancer patients.Results1、Bioinformatics analysis through the database showed that the expression of TRIM 14 gene in ovarian cancer tissues was significantly increased compared with that in normal ovarian tissues(P<0.05),and the expression level of TRIM14 was up-regulated with the increase of ovarian cancer stage(P=0.04).The expression level of TRIM 14 protein in epithelial ovarian cancer was significantly up-regulated compared with that in normal ovarian tissue.Kaplan-Meier Plotter database analysis showed that the low expression group of TRIM14 mRNA showed an advantage in progression free survival PFS compared with the high expression group of TRIM 14 mRNA(P<0.05),and this relationship persisted after chemotherapy treatment.But there was no significant correlation between TRIM 14 mRNA level and overall survival of OS(P>0.05).2、Immunohistochemical results showed that TRIM 14 was up-regulated in epithelial ovarian cancer.Real-time quantitative PCR results suggested that the expression of TRIM14 mRNA was up-regulated in platinum-resistant epithelial ovarian cancer tissues compared with platinum-sensitive epithelial ovarian cancer tissues(P<0.05).3、TRIM14 expression was associated with tumor FIGO stage(P=0.01),involvement of one or both ovaries(P=0.028),and disease recurrence status(P=0.01)grouping,but not with age group(P=0.188).Kapaln-Meier univariate survival analysis showed that the overall survival time OS of patients with high expression of TRIM14 was significantly lower than that of patients with low expression of TRIM14(P<0.01).Further multivariate COX regression analysis showed that high expression of TRIM 14 and disease recurrence were independent risk factors for poor overall survival of OS in epithelial ovarian cancer patients.ConclusionTRIM 14 is overexpressed in epithelial ovarian cancer.Overexpression of TRIM 14 is a risk factor for poor overall survival in patients with epithelial ovarian cancer.TRIM 14 can be used as a prognostic marker for epithelial ovarian cancer. |
PDF Full Text Request